Layoffs
Filter News
Found 415 articles
-
The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023. -
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs. -
How to Address a Layoff in Your Cover Letter
12/14/2023
Being laid off from your job can be difficult and confusing. To help you in your job search, we've explained how to address a layoff in your cover letter to help you land your dream job. -
The company’s fiscal report for 2023 details revenue losses of $539 million and layoffs of 1,100 employees but notes that future GLP-1 manufacturing revenues could help stabilize its finances.
-
BioTech Medics Continues to Execute Its Calcium Business Plans
11/20/2023
BioTech Medics, Inc. is pleased to announce that the Company continues to build the fundamental substructure that will enhance our ability to raise capital to position the organization in a competitive advantage with its calcium carbonate assets to enhance BMCS as a substantial publicly traded firm in this sector.
-
On the heels of cutting 100 jobs in Ireland, Pfizer is laying off around 500 workers from its Sandwich, Kent facility in the U.K. under its cost-reduction plan to save $3.5 billion through 2024. -
Seeking to weather declining sales from its COVID-19 business in the third quarter, Pfizer is laying off approximately 200 employees at its manufacturing facility in Kalamazoo, Michigan.
-
In its most recent round of layoffs this year, the California-based biopharma company is letting go of 350 former Horizon Therapeutics staff whose roles overlap with existing positions at Amgen.
-
A revised Paxlovid supply agreement with the U.S. government has pushed Pfizer to launch a “cost realignment” program including layoffs, though it is still unclear how many employees will be affected.
-
The layoffs, set to take effect in late November, will impact about a third of Reata’s headcount. The workforce reduction comes just weeks after Biogen completed its $7.3 billion Reata buy. -
The companies have announced the impending closures of their respective businesses. Histogen will lay off most of its employees by the end of September. Fresh Tracks will do so by early October. -
Citing a challenging macro environment, 2seventy bio is launching a sweeping strategic reorganization that will see 40% of its staff laid off and CEO Nick Leschly stepping down. -
Week in Review: Amgen-Horizon Deal Moves Forward, First 10 Drugs for IRA Price Negotiation, Layof...
9/1/2023
$27.8B Amgen-Horizon deal gets FTC clearance with restrictions; the White House names first 10 drugs subject to Medicare price negotiations; Sage Therapeutics axes 40% of staff. -
Following the FDA’s recent rejection of zuranolone in major depressive disorder, Sage Therapeutics has launched a strategic reorganization initiative including a 40% reduction in headcount.
-
After the regulator rejected avasopasem manganese, its candidate for severe oral mucositis, Galera is implementing a restructuring initiative that involves reducing its headcount by 70%. -
Week in Review: Biogen M&A and Layoffs, Earnings Season Heats Up, and 12 Neuro Companies to Watch
7/28/2023
Biogen’s $7.3 billion Reata acquisition and layoffs dominated this week’s news, while BMS and Roche reported second-quarter earnings and BioSpace looked at 12 late-stage neuro companies. -
Illumina is laying off 79 workers in San Diego, and according to an internal email, more layoffs will be announced soon. -
The layoffs are a result of Sumitomo’s decision announced in April to combine its seven subsidiaries into one company. -
The latest round of layoffs comes just two months after Thermo Fisher announced plans to close three sites in San Diego, bringing the total to nearly 600 jobs cut in 2023. -
The AI drug discovery company’s reorganization will include laying off around 180 employees and dropping its atopic dermatitis candidate BEN-2293 in an effort to save nearly $56 million.